Ambu falls after 2021/22 guidance cut

Ambu A/S

08/02/2022 08:27

** Shares of Ambu  AMBUb.CO  fall around 4% after the Danish
medical device maker lowered its 2021/22 guidance
    ** Ambu revised its guidance to the bottom end of previous
range citing uncertainties from continued impact of Omicron,
saying it now expects FY organic growth of 15% and EBIT margin
of 7% or higher  urn:newsml:reuters.com:*:nGNE4KbbSv
    ** Consensus expectations assumed organic growth of 17%,
JPMorgan says
    ** The brokerage adds that Ambu's comments on challenges to
hospital access impacting Duodenoscope adoption, and also
indication of Gastroscope pricing at $350, below JPM's estimate
of $500, will likely be disappointing for long-term holders
    ** The stock, which falls to its lowest in two years, is
among worst performers on STOXX 600  .STOXX  index
    

 ((aleksandra.jasiurska@thomsonreuters.com))